These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34028533)

  • 21. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat.
    Blaauw Y; Gögelein H; Tieleman RG; van Hunnik A; Schotten U; Allessie MA
    Circulation; 2004 Sep; 110(13):1717-24. PubMed ID: 15364815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TASK-1 and TASK-3 may form heterodimers in human atrial cardiomyocytes.
    Rinné S; Kiper AK; Schlichthörl G; Dittmann S; Netter MF; Limberg SH; Silbernagel N; Zuzarte M; Moosdorf R; Wulf H; Schulze-Bahr E; Rolfes C; Decher N
    J Mol Cell Cardiol; 2015 Apr; 81():71-80. PubMed ID: 25655935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Termination of Vernakalant-Resistant Atrial Fibrillation by Inhibition of Small-Conductance Ca
    Diness JG; Skibsbye L; Simó-Vicens R; Santos JL; Lundegaard P; Citerni C; Sauter DRP; Bomholtz SH; Svendsen JH; Olesen SP; Sørensen US; Jespersen T; Grunnet M; Bentzen BH
    Circ Arrhythm Electrophysiol; 2017 Oct; 10(10):e005125. PubMed ID: 29018164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo.
    Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
    Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
    Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation.
    Baczko I; Liknes D; Yang W; Hamming KC; Searle G; Jaeger K; Husti Z; Juhasz V; Klausz G; Pap R; Saghy L; Varro A; Dolinsky V; Wang S; Rauniyar V; Hall D; Dyck JR; Light PE
    Br J Pharmacol; 2014 Jan; 171(1):92-106. PubMed ID: 24102184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel approaches for pharmacological management of atrial fibrillation.
    Ehrlich JR; Nattel S
    Drugs; 2009; 69(7):757-74. PubMed ID: 19441867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.
    Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Oct; 385(10):1003-16. PubMed ID: 22790794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TASK-1 current is inhibited by phosphorylation during human and canine chronic atrial fibrillation.
    Harleton E; Besana A; Chandra P; Danilo P; Rosen TS; Rosen MR; Argenziano M; Robinson RB; Feinmark SJ
    Am J Physiol Heart Circ Physiol; 2015 Jan; 308(2):H126-34. PubMed ID: 25437921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation.
    Voigt N; Rozmaritsa N; Trausch A; Zimniak T; Christ T; Wettwer E; Matschke K; Dobrev D; Ravens U
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Mar; 381(3):251-9. PubMed ID: 19760273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of small-conductance Ca2+-activated K+ channels terminates and protects against atrial fibrillation.
    Diness JG; Sørensen US; Nissen JD; Al-Shahib B; Jespersen T; Grunnet M; Hansen RS
    Circ Arrhythm Electrophysiol; 2010 Aug; 3(4):380-90. PubMed ID: 20562443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic inhibition of small-conductance calcium-activated potassium (SK) channels by NS8593 reveals atrial antiarrhythmic potential in horses.
    Haugaard MM; Hesselkilde EZ; Pehrson S; Carstensen H; Flethøj M; Præstegaard KF; Sørensen US; Diness JG; Grunnet M; Buhl R; Jespersen T
    Heart Rhythm; 2015 Apr; 12(4):825-35. PubMed ID: 25542425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic management of atrial fibrillation: current therapeutic strategies.
    Lévy S
    Am Heart J; 2001 Feb; 141(2 Suppl):S15-21. PubMed ID: 11174354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?
    Kiper AK; Rinné S; Rolfes C; Ramírez D; Seebohm G; Netter MF; González W; Decher N
    Pflugers Arch; 2015 May; 467(5):1081-90. PubMed ID: 25511502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiarrhythmic effect of the Ca
    Kirchhoff JE; Diness JG; Abildgaard L; Sheykhzade M; Grunnet M; Jespersen T
    Pflugers Arch; 2016 Nov; 468(11-12):1853-1863. PubMed ID: 27722784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNAs Regulate TASK-1 and Are Linked to Myocardial Dilatation in Atrial Fibrillation.
    Wiedmann F; Kraft M; Kallenberger S; Büscher A; Paasche A; Blochberger PL; Seeger T; Jávorszky N; Warnecke G; Arif R; Kremer J; Karck M; Frey N; Schmidt C
    J Am Heart Assoc; 2022 Apr; 11(7):e023472. PubMed ID: 35301863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of K(2P)3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation.
    Schmidt C; Wiedmann F; Voigt N; Zhou XB; Heijman J; Lang S; Albert V; Kallenberger S; Ruhparwar A; Szabó G; Kallenbach K; Karck M; Borggrefe M; Biliczki P; Ehrlich JR; Baczkó I; Lugenbiel P; Schweizer PA; Donner BC; Katus HA; Dobrev D; Thomas D
    Circulation; 2015 Jul; 132(2):82-92. PubMed ID: 25951834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
    Wettwer E; Christ T; Endig S; Rozmaritsa N; Matschke K; Lynch JJ; Pourrier M; Gibson JK; Fedida D; Knaut M; Ravens U
    Cardiovasc Res; 2013 Apr; 98(1):145-54. PubMed ID: 23341576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels.
    Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D
    Eur J Pharmacol; 2013 Dec; 721(1-3):237-48. PubMed ID: 24070813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the ventilatory stimulant, doxapram on human TASK-3 (KCNK9, K2P9.1) channels and TASK-1 (KCNK3, K2P3.1) channels.
    Cunningham KP; MacIntyre DE; Mathie A; Veale EL
    Acta Physiol (Oxf); 2020 Feb; 228(2):e13361. PubMed ID: 31423744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.